MXPA04003631A - Rosuvastatina en estados de pre-demencia. - Google Patents

Rosuvastatina en estados de pre-demencia.

Info

Publication number
MXPA04003631A
MXPA04003631A MXPA04003631A MXPA04003631A MXPA04003631A MX PA04003631 A MXPA04003631 A MX PA04003631A MX PA04003631 A MXPA04003631 A MX PA04003631A MX PA04003631 A MXPA04003631 A MX PA04003631A MX PA04003631 A MXPA04003631 A MX PA04003631A
Authority
MX
Mexico
Prior art keywords
rosuvastatin
demented
states
patient
dementia
Prior art date
Application number
MXPA04003631A
Other languages
English (en)
Spanish (es)
Inventor
Rak Ihor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04003631A publication Critical patent/MXPA04003631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
MXPA04003631A 2001-10-19 2002-10-18 Rosuvastatina en estados de pre-demencia. MXPA04003631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103509A SE0103509D0 (sv) 2001-10-19 2001-10-19 Rosuvastatin in pre demented states
PCT/SE2002/001911 WO2003032995A1 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states

Publications (1)

Publication Number Publication Date
MXPA04003631A true MXPA04003631A (es) 2004-07-30

Family

ID=20285721

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003631A MXPA04003631A (es) 2001-10-19 2002-10-18 Rosuvastatina en estados de pre-demencia.

Country Status (19)

Country Link
US (1) US20060229321A1 (enExample)
EP (1) EP1446123A1 (enExample)
JP (1) JP2005505605A (enExample)
KR (1) KR20040058201A (enExample)
CN (1) CN1604780A (enExample)
AR (1) AR036891A1 (enExample)
BR (1) BR0213434A (enExample)
CA (1) CA2463597A1 (enExample)
CO (1) CO5580773A2 (enExample)
HU (1) HUP0401798A3 (enExample)
IL (1) IL161380A0 (enExample)
IS (1) IS7218A (enExample)
MX (1) MXPA04003631A (enExample)
NO (1) NO20041840L (enExample)
PL (1) PL369573A1 (enExample)
RU (1) RU2004112422A (enExample)
SE (1) SE0103509D0 (enExample)
WO (1) WO2003032995A1 (enExample)
ZA (1) ZA200402844B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
WO2006017357A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
TWI345562B (en) 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
KR20070062996A (ko) 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol

Also Published As

Publication number Publication date
US20060229321A1 (en) 2006-10-12
EP1446123A1 (en) 2004-08-18
PL369573A1 (en) 2005-05-02
HUP0401798A3 (en) 2005-06-28
RU2004112422A (ru) 2005-04-10
BR0213434A (pt) 2004-11-09
HUP0401798A2 (hu) 2005-01-28
ZA200402844B (en) 2005-01-24
CN1604780A (zh) 2005-04-06
CA2463597A1 (en) 2003-04-24
SE0103509D0 (sv) 2001-10-19
WO2003032995A1 (en) 2003-04-24
IL161380A0 (en) 2004-09-27
JP2005505605A (ja) 2005-02-24
WO2003032995A8 (en) 2004-06-03
AR036891A1 (es) 2004-10-13
NO20041840L (no) 2004-05-05
CO5580773A2 (es) 2005-11-30
KR20040058201A (ko) 2004-07-03
IS7218A (is) 2004-04-13

Similar Documents

Publication Publication Date Title
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
IL152770A0 (en) Gabapentin analogues for sleep disorders
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
MY127290A (en) New use of flibanserin
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
EA200400881A1 (ru) Азаарилпиперазины
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
GB0130677D0 (en) Medicaments and novel compounds
DE50201780D1 (de) Halogensubstituierte aminodicarbonsäurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen
NO20051892L (no) Ny forbindelse
NO20051893L (no) Ny forbindelse
SE0103509D0 (sv) Rosuvastatin in pre demented states
GB0020504D0 (en) Therapeutic method
GB0228045D0 (en) Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith
EP0866711A4 (en) METHOD FOR PREVENTING SLEEP APNOE
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
MEP5608A (xx) Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
WO2002015894A3 (en) Use of vitamin d derivatives as bone resorption inhibitors
DE60315666D1 (de) Furopyridin- und furopyrimidinderivate zur behandlung von hyperproliferativen erkrankungen
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
AU2002211217A1 (en) Method of treating stroke

Legal Events

Date Code Title Description
FA Abandonment or withdrawal